Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Amgen Beats Q2 Estimates – Adjusts Outlook

By John F. Heerdink, Jr.

Reportedly, Amgen exceeded Q2 estimates reporting $4.38 per share, minus some items, on $6.53 billion in sales. Earnings increased 4% year over year and exceeded analysts’ estimate for $4.09 per share. Sales topped expectations for $6.46 billion and increased 5%. Across all medicines, volumes grew 8% while sales prices declined 5%.

Sales of the company’s biggest moneymaker, an arthritis drug called Enbrel, declined on lower sales price and volumes. Its osteoporosis treatment Prolia and cholesterol med Repatha reported double-digit growth, an increase of respective 24% and 43% year over year.  The company reported 30% sales growth for Evenity, a postmenopausal treatment for osteoporosis, with volumes increasing 32% and sales reaching $131 million. Sales of migraine medicine Aimovig and psoriasis drug Otezla decreased respectively 16% and 5% year over year. 

The giant biotech company predicts adjusted earnings of $16-$17 per share and $25.8 billion to $26.6 billion in sales for the year.

If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus. 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.

(Read Original Story: Amgen Stock Dips On Guidance Trim Despite Second-Quarter Beat in Investor's Business Daily)


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us